Clinical effect of anti-D immunoglobulin in treatment of childhood immune thrombocytopenia: a Meta analysis / 中国当代儿科杂志
Chinese Journal of Contemporary Pediatrics
;
(12): 1070-1076, 2017.
Artigo
em Chinês
| WPRIM
| ID: wpr-300446
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the clinical effect and safety of anti-D immunoglobulin (anti-D) in the treatment of children with newly diagnosed acute immune thrombocytopenia (ITP) through a Meta analysis.</p><p><b>METHODS</b>PubMed, EMBASE, Cohrane Library, Ovid, CNKI, and Wanfang Data were searched for randomized controlled trials (RCTs) published up to April 2017. Review Manager 5.3 was used for the Meta analysis.</p><p><b>RESULTS</b>Seven RCTs were included. The Meta analysis showed that after 72 hours and 7 days of treatment, the intravenous immunoglobulin (IVIG) group had a significantly higher percentage of children who achieved platelet count >20×10/L than the anti-D group (P<0.05). There were no significant differences in platelet count after 24 hours, 72 hours, and 7 days of treatment between the anti-D (50 μg/kg) group and the IVIG group (P>0.05), and there were also no significant differences in platelet count after 24 hours and 7 days of treatment between the 50 μg/kg and 75 μg/kg anti-D groups (P>0.05). The anti-D group had a significantly greater reduction in the hemoglobin level than the IVIG group after treatment, but did not need transfusion. No children in the anti-D group or the IVIG group experienced serious adverse reactions.</p><p><b>CONCLUSIONS</b>Intravenous injection of anti-D may have a similar effect as IVIG in improving platelet count in children with acute ITP, but it may be slightly inferior to IVIG in the rate of platelet increase after treatment. The anti-D dose of 50 μg/kg may have a similar effect as 75 μg/kg. The recommended dose of anti-D for treatment of ITP is safe.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Contagem de Plaquetas
/
Sangue
/
Púrpura Trombocitopênica Idiopática
/
Imunoglobulinas Intravenosas
/
Imunoglobulina rho(D)
/
Usos Terapêuticos
/
Tratamento Farmacológico
Tipo de estudo:
Ensaio Clínico Controlado
/
Revisões Sistemáticas Avaliadas
Limite:
Humanos
Idioma:
Chinês
Revista:
Chinese Journal of Contemporary Pediatrics
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS